Cargando…

Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy

BACKGROUND: Lipid metabolism has been recently reported to affect the prognosis and tumor immune activity in cancer patients. However, the effect of lipid metabolism on chemosensitivity in patients with breast cancer treated with neoadjuvant chemotherapy (NAC) remains unclear. METHODS: We examined 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Wataru, Kashiwagi, Shinichiro, Takada, Koji, Asano, Yuka, Ogisawa, Kana, Morisaki, Tamami, Shibutani, Masatsune, Tanaka, Hiroaki, Maeda, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806883/
https://www.ncbi.nlm.nih.gov/pubmed/36593486
http://dx.doi.org/10.1186/s40001-022-00964-w
_version_ 1784862608407396352
author Goto, Wataru
Kashiwagi, Shinichiro
Takada, Koji
Asano, Yuka
Ogisawa, Kana
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Maeda, Kiyoshi
author_facet Goto, Wataru
Kashiwagi, Shinichiro
Takada, Koji
Asano, Yuka
Ogisawa, Kana
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Maeda, Kiyoshi
author_sort Goto, Wataru
collection PubMed
description BACKGROUND: Lipid metabolism has been recently reported to affect the prognosis and tumor immune activity in cancer patients. However, the effect of lipid metabolism on chemosensitivity in patients with breast cancer treated with neoadjuvant chemotherapy (NAC) remains unclear. METHODS: We examined 327 patients with breast cancer who were treated with NAC followed by curative surgery. The correlations between the serum levels of total cholesterol (TC) and triglyceride (TG) and the clinicopathological features, including the efficacy of NAC, neutrophil-to-lymphocyte ratio (NLR), and absolute lymphocyte count (ALC), were evaluated retrospectively. RESULTS: Serum TG levels were increased after NAC in all the subtypes, and the rate of change was the highest, especially in triple-negative breast cancer (TNBC) (21.0% → 48.1%). In addition, only TNBC patients with an objective response (OR) had significantly higher TG levels after NAC than those without (P = 0.049). Patients with a high ALC before NAC had significantly higher TG levels after NAC than patients with all breast cancer (P = 0.001), HER2-enriched breast cancer (P = 0.021), and TNBC (P = 0.008). Patients with a low NLR before NAC had significantly higher TG levels after NAC only among patients with TNBC (P = 0.025). In patients with human epidermal growth factor receptor 2-enriched breast cancer, the group with normal TC levels before NAC had significantly better OS than those with high TC levels (P = 0.013, log-rank test), and in patients with TNBC, the group with high TC levels after NAC had significantly better OS than those with normal TC levels (P = 0.014, log-rank test). CONCLUSIONS: Good systemic immune activity and chemosensitivity may be associated with lipid metabolism regulated by NAC in TNBC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-022-00964-w.
format Online
Article
Text
id pubmed-9806883
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98068832023-01-03 Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy Goto, Wataru Kashiwagi, Shinichiro Takada, Koji Asano, Yuka Ogisawa, Kana Morisaki, Tamami Shibutani, Masatsune Tanaka, Hiroaki Maeda, Kiyoshi Eur J Med Res Research BACKGROUND: Lipid metabolism has been recently reported to affect the prognosis and tumor immune activity in cancer patients. However, the effect of lipid metabolism on chemosensitivity in patients with breast cancer treated with neoadjuvant chemotherapy (NAC) remains unclear. METHODS: We examined 327 patients with breast cancer who were treated with NAC followed by curative surgery. The correlations between the serum levels of total cholesterol (TC) and triglyceride (TG) and the clinicopathological features, including the efficacy of NAC, neutrophil-to-lymphocyte ratio (NLR), and absolute lymphocyte count (ALC), were evaluated retrospectively. RESULTS: Serum TG levels were increased after NAC in all the subtypes, and the rate of change was the highest, especially in triple-negative breast cancer (TNBC) (21.0% → 48.1%). In addition, only TNBC patients with an objective response (OR) had significantly higher TG levels after NAC than those without (P = 0.049). Patients with a high ALC before NAC had significantly higher TG levels after NAC than patients with all breast cancer (P = 0.001), HER2-enriched breast cancer (P = 0.021), and TNBC (P = 0.008). Patients with a low NLR before NAC had significantly higher TG levels after NAC only among patients with TNBC (P = 0.025). In patients with human epidermal growth factor receptor 2-enriched breast cancer, the group with normal TC levels before NAC had significantly better OS than those with high TC levels (P = 0.013, log-rank test), and in patients with TNBC, the group with high TC levels after NAC had significantly better OS than those with normal TC levels (P = 0.014, log-rank test). CONCLUSIONS: Good systemic immune activity and chemosensitivity may be associated with lipid metabolism regulated by NAC in TNBC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-022-00964-w. BioMed Central 2023-01-02 /pmc/articles/PMC9806883/ /pubmed/36593486 http://dx.doi.org/10.1186/s40001-022-00964-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Goto, Wataru
Kashiwagi, Shinichiro
Takada, Koji
Asano, Yuka
Ogisawa, Kana
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Maeda, Kiyoshi
Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy
title Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy
title_full Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy
title_fullStr Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy
title_full_unstemmed Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy
title_short Clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy
title_sort clinical verification of the relationship between serum lipid metabolism and immune activity in breast cancer patients treated with neoadjuvant chemotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806883/
https://www.ncbi.nlm.nih.gov/pubmed/36593486
http://dx.doi.org/10.1186/s40001-022-00964-w
work_keys_str_mv AT gotowataru clinicalverificationoftherelationshipbetweenserumlipidmetabolismandimmuneactivityinbreastcancerpatientstreatedwithneoadjuvantchemotherapy
AT kashiwagishinichiro clinicalverificationoftherelationshipbetweenserumlipidmetabolismandimmuneactivityinbreastcancerpatientstreatedwithneoadjuvantchemotherapy
AT takadakoji clinicalverificationoftherelationshipbetweenserumlipidmetabolismandimmuneactivityinbreastcancerpatientstreatedwithneoadjuvantchemotherapy
AT asanoyuka clinicalverificationoftherelationshipbetweenserumlipidmetabolismandimmuneactivityinbreastcancerpatientstreatedwithneoadjuvantchemotherapy
AT ogisawakana clinicalverificationoftherelationshipbetweenserumlipidmetabolismandimmuneactivityinbreastcancerpatientstreatedwithneoadjuvantchemotherapy
AT morisakitamami clinicalverificationoftherelationshipbetweenserumlipidmetabolismandimmuneactivityinbreastcancerpatientstreatedwithneoadjuvantchemotherapy
AT shibutanimasatsune clinicalverificationoftherelationshipbetweenserumlipidmetabolismandimmuneactivityinbreastcancerpatientstreatedwithneoadjuvantchemotherapy
AT tanakahiroaki clinicalverificationoftherelationshipbetweenserumlipidmetabolismandimmuneactivityinbreastcancerpatientstreatedwithneoadjuvantchemotherapy
AT maedakiyoshi clinicalverificationoftherelationshipbetweenserumlipidmetabolismandimmuneactivityinbreastcancerpatientstreatedwithneoadjuvantchemotherapy